Symbols

SNTI

Senti Biosciences·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 2

Gap Down

Significant Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SNTI

Senti Biosciences, Inc.

A biotech company that innovating cell and gene therapies using its proprietary gene circuit platform

Industry

Biological Technology

Established Date

03/01/2021

Listing Date

05/26/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.sentibio.com

Security Type

Common stock

Office address

2 Corporate Drive First Floor South San Francisco CA 94080

Business

Introduction

Senti Biosciences, Inc., was incorporated in Delaware on March 1, 2021. The company is a clinical-stage biotechnology company that leverages its gene circuit platform technology to develop next-generation cell and gene therapies for patients with incurable diseases. The company's mission is to create a new generation of smarter medicines that use novel and unprecedented methods to defeat complex diseases.

Company Financials

EPS

SNTI has released its 2025 Q4 earnings. EPS was reported at -0.53, versus the expected -0.41, missing expectations. The chart below visualizes how SNTI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SNTI has released its 2025 Q4 earnings report, with revenue of 22.00K, reflecting a YoY change of NaN%, and net profit of -14.47M, showing a YoY change of -2271.64%. The Sankey diagram below clearly presents SNTI's revenue sources and cost distribution.